Two-Year EVOLVE II Data Support Boston Scientific's Synergy DES

April 3, 2016—Two-year data from the EVOLVE II trial supporting outcomes, including safety, with Boston Scientific’s Synergy bioabsorbable polymer drug-eluting stent (DES) system were presented at ACC.16, the American College of Cardiology’s 65th annual scientific session held April 2–4 in Chicago, Illinois. Dean Kereiakes, MD, who is from The Christ Hospital Heart and Vascular Center, in Cincinnati, Ohio, is Principal Investigator of EVOLVE II.

According to Boston Scientific, the Synergy stent demonstrated zero definite stent thrombosis (ST) at 24 hours after implantation and exceptionally low definite/probable ST at 2 years in EVOLVE II. In the real-world Swedish Coronary Angiography and Angioplasty Registry, or SCAAR, the Synergy stent showed the lowest ST rate of any bioabsorbable polymer or durable polymer DES beyond 1 year, noted Boston Scientific.

At 4 years, no patients with the Synergy stent experienced ST. 

Additionally, after treatment with the Synergy stent, patients who discontinued dual-antiplatelet therapy (DAPT) at 3 months experienced a 0% rate of ST, myocardial infarction, or cardiac death.

The company noted that current guidelines have recommended patients stay on a DAPT from 9 to 12 months for DES postimplantation. Supported by the low rates of late and very late ST observed in clinical trials to date, the Synergy DES may enable shorter mandatory DAPT duration. This hypothesis is being tested in the EVOLVE Short DAPT trial, a prospective, global evaluation of 3-month DAPT duration after implantation of the Synergy stent. If successful, data from study will support an indication for shortened DAPT, advised Boston Scientific.